# Fidelity National

Type: Company (FNF)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/fidelity-national
Canonical HTML page: https://getbiobrief.com/entity/fidelity-national

## Recent coverage (1 stories)

### Iovance Q4 Preview: Amtagvi Commercial Trajectory and TIL Market Expansion
2026-02-23 17:01:20 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Iovance Biotherapeutics is set to report Q4 2025 results, marking a full year of commercial operations for its breakthrough TIL therapy, Amtagvi. The update will be a critical indicator of the company's ability to scale complex cell therapy logistics and expand its market presence in oncology.
Full story: https://getbiobrief.com/story/iovance-q4-2025-earnings-preview-amtagvi-til-therapy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.